Valbiotis celebrates the success of the INSIGHT study on TOTUM•854

Valbiotis announced the conclusive results of the INSIGHT clinical study on TOTUM•854. This study demonstrated the efficacy of the product in reducing systolic blood pressure (SBP) in individuals with untreated mild hypertension. The primary efficacy endpoint was met, showing a significant reduction of -9 mmHg in SBP after three months of treatment compared to placebo.

The study involved more than 400 participants and revealed excellent tolerance and safety of TOTUM•854. This product thus becomes the third from Valbiotis to prove its clinical efficacy, after Lipidrive® for hypercholesterolemia and TOTUM-63 for prediabetes.

These results mark a significant milestone for Valbiotis, reinforcing its approach based on innovative combinations of plant-based active ingredients. The company plans to share the findings at international conferences and in scientific publications. TOTUM•854 could offer a promising non-drug solution to reduce SBP and prevent cardiovascular diseases.